The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral ...

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and oxidative stress.

Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SH-110, a ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Orphan nuclear receptors influence the onset and progression of MASLD, particularly in lipid metabolism, inflammation, ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...